The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 Aastrom Biosciences Inc.  (ASTM) Trade Now »     Rate ASTM  -  Discuss ASTM  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
This is a micro-cap stock and may be a target of manipulation. Always do your research!

SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
78.5%
Top:
100.0%
Rate ASTM:


Home
Analysis & Videos
Quotes
Bull or Bear
Discuss
        

ASTM: Bull or Bear? From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

Aastrom Biosciences Inc. Graphic_rating_buy ASTM
Foto
62%
 -29.67%
in 142 days

http://www.chartmoney.com/stockquotes.php?ticker=astm
Aastrom Biosciences Inc., which develops adult stem cells to treat heart diseases, said Thursday the Food and Drug Administration has lifted a halt on a clinical trial.ces Inc., which develops adult stem cells to treat heart diseases, said Thursday the Food and Drug Administration has lifted a halt on a clinical trial.
By  Marian Filo   (-24.55%  risk: aggressive)  06/19/09 Comment


Index to Track New Era for Stem Cell Cos. Graphic_rating_buy ASTM
Mikerun
73%
 -54.21%
in 289 days
Index to Track New Era for Stem Cell Cos.
 
Shares of Geron (GERN) are soaring today by more than 40% on FDA approval to begin human clinical testing this summer for an embryonic stem cell treatment for spinal cord injuries. The approval comes just days after the new administration took office, breathing new life into related companies such as StemCells (STEM), Aastrom Biosciences (ASTM), and others tracked in the ETF Innovators Cosmetic & Reconstructive Medicine Index.
 
<> This index and new ETF idea represents a first-to-market idea to provide investors with an excha...
By  Mike Havrilla   (+1.04%  risk: conservative)  01/23/09 Comment




From the Blogosphere

Analysis of Stem Cell Index YTD
Mikerun
73%
The accompanying table includes statistics for the 40 companies in the ETF Innovators Global Stem Cell and Regenerative Medicine Index, which is down 13.8% at a value of 3,387 from a 2/22/09 inception date value of 3,928.

The index is down 30.6% over the past year on an equal-weight basis, compared to losses of 31.2% for the Healthcare Sector SPDR (XLV), 19% for iShares Nasdaq Biotech (IBB), 14.7% for SPDR S&P Biotech (XBI), 29.7% for PowerShares Biotech & Genome (PBE), and 46.1% for the S&P 500 SPDR (SPY).

Below is a profile for each company, including a summary of their business and researc...
By  Mike Havrilla   (+1.04%  risk: conservative)  03/08/09 Comment


Global Stem Cell and Regenerative Medicine Index
Mikerun
73%


The accompanying table (click to enlarge) includes 40 companies in the ETF Innovators Global Stem Cell and Regenerative Medicine Index, which represents an expansion of the Emerging Stem Cell Index I have written about previously. The expanded global index includes companies with market caps less than $1B at the index inception with a total market value of $3,814 as of the close today. As previously, I will track the total market value for a more comprehensive gauge of investor sentiment toward the space.

The index is down 16.2% over the past year on an equal-weight basis, compared to losses...
By  Mike Havrilla   (+1.04%  risk: conservative)  02/18/09 Comment


Stem Cell Index Down 7% in Past Week
Mikerun
73%


The accompanying table (click to enlarge) includes 26 companies in the ETF Innovators Emerging Stem Cell Index, which lost 7% of its market value in the past week (at 1,148 today) and posted a 15.2% loss over the past year on an equal-weight basis.

Results for benchmark indexes and ETFs include gains of 1.5% for the Cosmetic and Restorative Medicine Index and losses of 1.2% for SPDR S&P Biotech (XBI), 18.7% for Healthcare Sector SPDR (XLV), 7.2% for iShares Nasdaq Biotech (IBB), and 17.7% for PowerShares Biotech & Genome (PBE).

The next catalyst expected for stem cell and regenerative medicin...
By  Mike Havrilla   (+1.04%  risk: conservative)  02/15/09 Comment


An Expanded Emerging Stem Cell Index
Mikerun
73%

The accompanying table (click to enlarge) includes 32 companies in the ETF Innovators Emerging Stem Cell Index of U.S.-listed stocks with market caps below $250M. I will maintain the index with these 32 components and track the total market value and stock price changes as an indicator of investor and trader sentiment toward the stem cell and regenerative medicine space.

Below is a list of all 32 companies in descending order by market cap with a total value of $1.27B and an average stock price change of -15% over the past year for the index, as compared to losses of 20% for the Healthcare S...
By  Mike Havrilla   (+1.04%  risk: conservative)  02/04/09 Comment


New Emerging Stem Cell Index
Mikerun
73%


Shares of Geron (GERN) and other well known stem cell and regenerative medicine stocks such as Osiris Therapeutics (OSIR) and StemCells (STEM) have been soaring since the FDA allowed human clinical testing for Geron's embryonic stem cell treatment candidate for spinal cord injuries.

The accompanying table (click to enlarge) highlights 25 U.S.-listed stem cell and regenerative medicine companies with market caps of below $200M which are included in the ETF Innovators Emerging Stem Cell Index. The companies are also listed below in descending order by market cap.

BioMimetic Therapeutics (BMTI)
C...
By  Mike Havrilla   (+1.04%  risk: conservative)  02/02/09 Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +35.25% 368
2 Gerald Greene 18.14 +70.90% 206
3 stockmarketfunding.com 17.66 +25.78% 53
4 akiralegrand 13.47 +14.32% 60
5 anup2104 12.13 +69.23% 34


POPULAR STOCKS
Symbol Company Name Sentiment
V Visa Inc
T AT&T Inc
BAC Bank of America Corp
MO Altria Group Inc
MA MasterCard Inc
JPM JPMorgan Chase & Co

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on ASTM

Visit streetinsider.com


Discussion Wall + Add  
amritadas   (+0.00%)
Upcoming FDA decision on the approval of a new Gout.. - An upcoming treatment by a small cap company for Gout to face FDA decision on approval shortly. Gout has traditionally been a difficult disease to tre
+   0 replies

amritadas   (+0.00%)
A FREE report on the approval of a new Gout Drug - FDA Panel to review this Biotech company's stress agent drug on July 28th. If they get a favorable backing by the panel, the chances of approval by th...
+   0 replies

amritadas   (+0.00%)
Free report on upcoming FDA panel decision of Corvu.. - FDA Panel to review this Biotech company's stress agent drug on July 28th. If they get a favorable backing by the panel, the chances of approval by th...
+   0 replies


More Resources

Graphic_arrow1 About Aastrom Biosciences Inc. - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch